{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:51:10Z","timestamp":1774029070555,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Public Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prisoners are recognised as a high-risk population and prisons as high-risk locations for the transmission of hepatitis c virus (HCV) infection. Injecting drug use (IDU) is the main driver of HCV infection in prisoners and harm reduction services are often suboptimal in prison settings. HCV prevalence and incident data in prisoners is incomplete which impacts the public health opportunity that incarceration provides in identifying, treating and preventing HCV infection. The aim of this study is to identify new HCV infection and associated risk factors in an Irish male prison.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a follow up (18-month) cohort study on prisoners who had previously tested negative, self-cleared or had been successfully treated for HCV infection. We conducted the study in a male medium security prison located in Dublin Ireland (Mountjoy Prison) using HCV serology, a review of medical records and a researcher-administered questionnaire.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>99 prisoners with a mean age of 33.2\u2009yrs. participated in the study and 82(82.8%) completed a research-administered questionnaire. Over half (51%) had a history of drug use from a young age (14.8\u2009yrs.), 49.9% a history of heroin use and 39% a history of IDU. The prevalence of HIV and hepatitis B virus core antibody was 3% and HCV antibody was 22.2%. No new HCV infections were identified in those who had never been infected (<jats:italic>n<\/jats:italic>\u2009=\u200977), had self-cleared (<jats:italic>n<\/jats:italic>\u2009=\u20099) or achieved sustained virological response (<jats:italic>n<\/jats:italic>\u2009=\u200912). Small numbers of prisoners continued to engage in risk-behaviour including, IDU both in the prison (<jats:italic>n<\/jats:italic>\u2009=\u20092) and the community (<jats:italic>n<\/jats:italic>\u2009=\u20093), sharing syringes (<jats:italic>n<\/jats:italic>\u2009=\u20091) and drug taking paraphernalia (<jats:italic>n<\/jats:italic>\u2009=\u20096) and receiving non-sterile tattoos (<jats:italic>n\u2009=<\/jats:italic>\u00a03).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Despite the high numbers of Irish prisoners with a history of IDU and HCV infection, new HCV infection is low or non-existent in this population. Small numbers of prisoners continue to engage\u00a0in risk behaviour and larger studies are required to further understand HCV transmission in this cohort in an Irish and international context.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13690-021-00623-2","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T04:03:57Z","timestamp":1623125037000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["New hepatitis C virus infection, re-infection and associated risk behaviour in male Irish prisoners: a cohort study, 2019"],"prefix":"10.1186","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8491-9596","authenticated-orcid":false,"given":"Des","family":"Crowley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordana","family":"Avramovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Collette","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Halpin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Keevans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eamon","family":"Laird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"McKiernan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah Jayne","family":"Miggin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Murtagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen O.","family":"Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"O\u2019Meara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deirdre O.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"623_CR1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","volume":"388","author":"JD Stanaway","year":"2016","unstructured":"Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet. 2016;388:1081\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(16)30579-7.","journal-title":"Lancet."},{"key":"623_CR2","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5:e1192\u2013207. https:\/\/doi.org\/10.1016\/S2214-109X(17)30375-3.","journal-title":"Lancet Glob Health"},{"key":"623_CR3","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/hep.26387","volume":"58","author":"S Larney","year":"2013","unstructured":"Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis. Hepatology. 2013;58:1215\u201324. https:\/\/doi.org\/10.1002\/hep.26387.","journal-title":"Hepatology"},{"key":"623_CR4","unstructured":"Irish Prison Service. Irish Prison Service Annual Report 2017: Dublin; 2017. https:\/\/www.irishprisons.ie\/wp-content\/uploads\/documents_pdf\/IPS-annualreport-2017.pdf"},{"key":"623_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12954-018-0272-4","volume":"16","author":"I Delargy","year":"2019","unstructured":"Delargy I, Crowley D, Van Hout MC. Twenty years of the methadone treatment protocol in Ireland: reflections on the role of general practice. Harm Reduct J. 2019;16:5. https:\/\/doi.org\/10.1186\/s12954-018-0272-4.","journal-title":"Harm Reduct J"},{"key":"623_CR6","volume-title":"Study on the prevalence of drug use, including intravenous drug use, and blood-borne viruses among the Irish prisoner population","author":"A Drummond","year":"2014","unstructured":"Drummond A, Codd M, Donnelly N, McCausland D, Mehegan J, Daly L, et al. Study on the prevalence of drug use, including intravenous drug use, and blood-borne viruses among the Irish prisoner population. Dublin: National Advisory Committee on Drugs and Alcohol; 2014. https:\/\/www.drugsandalcohol.ie\/21750\/1\/Full-Drug-use-among-Irish-prisoner-population.pdf"},{"key":"623_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/bmj.321.7253.78","volume":"321","author":"S Allwright","year":"2000","unstructured":"Allwright S. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. BMJ. 2000;321:78\u201382. https:\/\/doi.org\/10.1136\/bmj.321.7253.78.","journal-title":"BMJ."},{"key":"623_CR8","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1186\/s12879-019-4218-6","volume":"19","author":"D Crowley","year":"2019","unstructured":"Crowley D, Murtagh R, Cullen W, Lambert JS, McHugh T, Van Hout MC. Hepatitis C virus infection in Irish drug users and prisoners \u2013 a scoping review. BMC Infect Dis. 2019;19:702. https:\/\/doi.org\/10.1186\/s12879-019-4218-6.","journal-title":"BMC Infect Dis"},{"key":"623_CR9","unstructured":"Department of Health. Hepatitis C Screening (NCEC National Clinical Guideline No. 15). Dublin; 2017. https:\/\/health.gov.ie\/wp-content\/uploads\/2017\/08\/Hepatitis-C-NCG-15_v8.pdf"},{"key":"623_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12954-019-0313-7","volume":"16","author":"D Crowley","year":"2019","unstructured":"Crowley D, Murtagh R, Cullen W, Keevans M, Laird E, McHugh T, et al. Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners. Harm Reduct J. 2019;16:42. https:\/\/doi.org\/10.1186\/s12954-019-0313-7.","journal-title":"Harm Reduct J"},{"key":"623_CR11","doi-asserted-by":"publisher","first-page":"1800369","DOI":"10.2807\/1560-7917.ES.2019.24.14.1800369","volume":"24","author":"D Crowley","year":"2019","unstructured":"Crowley D, Lambert JS, Betts-Symonds G, Cullen W, Keevans M, Kelly E, et al. The seroprevalence of untreated chronic hepatitis C virus (HCV) infection and associated risk factors in male Irish prisoners: a cross-sectional study, 2017. Eurosurveillance. 2019;24:1800369. https:\/\/doi.org\/10.2807\/1560-7917.ES.2019.24.14.1800369.","journal-title":"Eurosurveillance."},{"key":"623_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1108\/IJPH-11-2013-0051","volume":"10","author":"SG Larney","year":"2014","unstructured":"Larney SG, Beckwith CD, Zaller NT, Montague B, Rich J. \u201cSeek, test, treat and retain\u201d for hepatitis C in the United States criminal justice system. Int J Prison Health. 2014;10:164\u201371. https:\/\/doi.org\/10.1108\/IJPH-11-2013-0051.","journal-title":"Int J Prison Health"},{"key":"623_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3201\/eid2105.141832","volume":"21","author":"NA Breta\u00f1a","year":"2015","unstructured":"Breta\u00f1a NA, Boelen L, Bull R, Teutsch S, White PA, Lloyd AR, et al. Transmission of hepatitis C virus among prisoners, Australia, 2005\u20132012. Emerg Infect Dis. 2015;21:765\u201374. https:\/\/doi.org\/10.3201\/eid2105.141832.","journal-title":"Emerg Infect Dis"},{"key":"623_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.5694\/j.1326-5377.2001.tb143214.x","volume":"174","author":"JJ Post","year":"2001","unstructured":"Post JJ, Lloyd AR, Dolan KA, Whybin LR, Carter IWJ, Haber PS. Acute hepatitis C virus infection in an Australian prison inmate: tattooing as a possible transmission route. Med J Aust. 2001;174:183\u20134. https:\/\/doi.org\/10.5694\/j.1326-5377.2001.tb143214.x.","journal-title":"Med J Aust"},{"key":"623_CR15","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1093\/eurpub\/ckv133","volume":"25","author":"C Rumble","year":"2015","unstructured":"Rumble C, Pevalin DJ, O\u2019Moore \u00c9. Routine testing for blood-borne viruses in prisons: a systematic review. Eur J Pub Health. 2015;25:1078\u201388. https:\/\/doi.org\/10.1093\/eurpub\/ckv133.","journal-title":"Eur J Pub Health"},{"issue":"Suppl 6","key":"623_CR16","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1186\/1471-2334-14-S6-S17","volume":"14","author":"A Arain","year":"2014","unstructured":"Arain A, Robaeys G, St\u00f6ver H. Hepatitis C in European prisons: a call for an evidence-informed response. BMC Infect Dis. 2014;14(Suppl 6):S17. https:\/\/doi.org\/10.1186\/1471-2334-14-S6-S17.","journal-title":"BMC Infect Dis"},{"key":"623_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12954-018-0269-z","volume":"15","author":"D Crowley","year":"2018","unstructured":"Crowley D, Van Hout MC, Lambert JS, Kelly E, Murphy C, Cullen W. Barriers and facilitators to hepatitis C (HCV) screening and treatment\u2014a description of prisoners\u2019 perspective. Harm Reduct J. 2018;15:62. https:\/\/doi.org\/10.1186\/s12954-018-0269-z.","journal-title":"Harm Reduct J"},{"key":"623_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40352-018-0081-6","volume":"6","author":"D Crowley","year":"2018","unstructured":"Crowley D, Van Hout MC, Murphy C, Kelly E, Lambert JS, Cullen W. Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective - a qualitative exploration. Heal Justice. 2018;6:23. https:\/\/doi.org\/10.1186\/s40352-018-0081-6.","journal-title":"Heal Justice"},{"issue":"Supplement_5","key":"623_CR19","doi-asserted-by":"publisher","first-page":"v39","DOI":"10.1093\/jac\/dkz455","volume":"74","author":"S Barror","year":"2019","unstructured":"Barror S, Avramovic G, Oprea C, Surey J, Story A, Mac\u00edas J, et al. HepCare Europe: a service innovation project. HepCheck: enhancing HCV identification and linkage to care for vulnerable populations through intensified outreach screening. A prospective multisite feasibility study. J Antimicrob Chemother. 2019;74(Supplement_5):v39\u201346. https:\/\/doi.org\/10.1093\/jac\/dkz455.","journal-title":"J Antimicrob Chemother"},{"key":"623_CR20","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/COH.0000000000000179","volume":"10","author":"NK Martin","year":"2015","unstructured":"Martin NK, Vickerman P, Dore GJ, Hickman M. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM). Curr Opin HIV AIDS. 2015;10:374\u201380. https:\/\/doi.org\/10.1097\/COH.0000000000000179.","journal-title":"Curr Opin HIV AIDS"},{"key":"623_CR21","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/S0140-6736(16)30856-X","volume":"388","author":"FL Altice","year":"2016","unstructured":"Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S, et al. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016;388:1228\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(16)30856-X.","journal-title":"Lancet."},{"issue":"suppl_2","key":"623_CR22","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1093\/cid\/cit265","volume":"57","author":"JJ Post","year":"2013","unstructured":"Post JJ, Arain A, Lloyd AR. Enhancing Assessment and Treatment of Hepatitis C in the Custodial Setting. Clin Infect Dis. 2013;57(suppl_2):S70\u20134. https:\/\/doi.org\/10.1093\/cid\/cit265.","journal-title":"Clin Infect Dis"},{"key":"623_CR23","doi-asserted-by":"publisher","first-page":"e0220297","DOI":"10.1371\/journal.pone.0220297","volume":"14","author":"J S\u00f8holm","year":"2019","unstructured":"S\u00f8holm J, Holm DK, M\u00f6ssner B, Madsen LW, Hansen JF, Weis N, et al. Incidence, prevalence and risk factors for hepatitis C in Danish prisons. PLoS One. 2019;14:e0220297. https:\/\/doi.org\/10.1371\/journal.pone.0220297.","journal-title":"PLoS One"},{"key":"623_CR24","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1111\/add.12643","volume":"109","author":"F Luciani","year":"2014","unstructured":"Luciani F. Breta\u00f1a NA rvi., Teutsch S, Amin J, Topp L, Dore GJ, et al. a prospective study of hepatitis C incidence in Australian prisoners. Addiction. 2014;109:1695\u2013706. https:\/\/doi.org\/10.1111\/add.12643.","journal-title":"Addiction."},{"key":"623_CR25","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/add.12107","volume":"108","author":"A Taylor","year":"2013","unstructured":"Taylor A, Munro A, Allen E, Dunleavy K, Cameron S, Miller L, et al. Low incidence of hepatitis C virus among prisoners in Scotland. Addiction. 2013;108:1296\u2013304. https:\/\/doi.org\/10.1111\/add.12107.","journal-title":"Addiction."},{"key":"623_CR26","doi-asserted-by":"publisher","first-page":"e90560","DOI":"10.1371\/journal.pone.0090560","volume":"9","author":"A Marco","year":"2014","unstructured":"Marco A, Gallego C, Cayl\u00e0 JA. Incidence of hepatitis C infection among prisoners by routine laboratory values during a 20-year period. PLoS One. 2014;9:e90560. https:\/\/doi.org\/10.1371\/journal.pone.0090560.","journal-title":"PLoS One"},{"key":"623_CR27","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1360-0443.2011.03676.x","volume":"107","author":"D Hedrich","year":"2012","unstructured":"Hedrich D, Alves P, Farrell M, St\u00f6ver H, M\u00f8ller L, Mayet S. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction. 2012;107:501\u201317. https:\/\/doi.org\/10.1111\/j.1360-0443.2011.03676.x.","journal-title":"Addiction."},{"key":"623_CR28","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/jvh.12580","volume":"23","author":"EJ Aspinall","year":"2016","unstructured":"Aspinall EJ, Mitchell W, Schofield J, Cairns A, Lamond S, Bramley P, et al. A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. J Viral Hepat. 2016;23:1009\u201316. https:\/\/doi.org\/10.1111\/jvh.12580.","journal-title":"J Viral Hepat"},{"key":"623_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/jvh.12666","volume":"24","author":"M Martinello","year":"2017","unstructured":"Martinello M, Grebely J, Petoumenos K, Gane E, Hellard M, Shaw D, et al. HCV reinfection incidence among individuals treated for recent infection. J Viral Hepat. 2017;24:359\u201370. https:\/\/doi.org\/10.1111\/jvh.12666.","journal-title":"J Viral Hepat"},{"key":"623_CR30","doi-asserted-by":"publisher","first-page":"546","DOI":"10.7326\/M14-0602","volume":"161","author":"S Liu","year":"2014","unstructured":"Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD. Sofosbuvir-Based Treatment Regimens for Chronic, Genotype 1 Hepatitis C Virus Infection in U.S. Incarcerated Populations. Ann Intern Med. 2014;161:546. https:\/\/doi.org\/10.7326\/M14-0602.","journal-title":"Ann Intern Med"},{"key":"623_CR31","doi-asserted-by":"publisher","unstructured":"Marco A, Esteban JI, Sol\u00e9 C, da Silva A, Ortiz J, Roget M, et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol. 2013;59:45\u201351. https:\/\/doi.org\/10.1016\/j.jhep.2013.03.008.","DOI":"10.1016\/j.jhep.2013.03.008"},{"key":"623_CR32","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1111\/j.1360-0443.2010.02990.x","volume":"105","author":"ELC Merrall","year":"2010","unstructured":"Merrall ELC, Kariminia A, Binswanger IA, Hobbs MS, Farrell M, Marsden J, et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010;105:1545\u201354. https:\/\/doi.org\/10.1111\/j.1360-0443.2010.02990.x.","journal-title":"Addiction."},{"key":"623_CR33","doi-asserted-by":"publisher","first-page":"592","DOI":"10.7326\/0003-4819-159-9-201311050-00005","volume":"159","author":"IA Binswanger","year":"2013","unstructured":"Binswanger IA. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159:592. https:\/\/doi.org\/10.7326\/0003-4819-159-9-201311050-00005.","journal-title":"Ann Intern Med"},{"key":"623_CR34","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1111\/add.13783","volume":"112","author":"J Stone","year":"2017","unstructured":"Stone J, Martin NK, Hickman M, Hutchinson SJ, Aspinall E, Taylor A, et al. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction. 2017;112:1302\u201314. https:\/\/doi.org\/10.1111\/add.13783.","journal-title":"Addiction."},{"key":"623_CR35","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1111\/add.12536","volume":"109","author":"L Degenhardt","year":"2014","unstructured":"Degenhardt L, Larney S, Kimber J, Gisev N, Farrell M, Dobbins T, et al. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction. 2014;109:1306\u201317. https:\/\/doi.org\/10.1111\/add.12536.","journal-title":"Addiction."},{"key":"623_CR36","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10654-007-9134-1","volume":"22","author":"A Kariminia","year":"2007","unstructured":"Kariminia A, Law MG, Butler TG, Corben SP, Levy MH, Kaldor JM, et al. Factors associated with mortality in a cohort of Australian prisoners. Eur J Epidemiol. 2007;22:417\u201328. https:\/\/doi.org\/10.1007\/s10654-007-9134-1.","journal-title":"Eur J Epidemiol"},{"issue":"suppl_2","key":"623_CR37","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1093\/cid\/cit306","volume":"57","author":"EJ Aspinall","year":"2013","unstructured":"Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis. Clin Infect Dis. 2013;57(suppl_2):S80\u20139. https:\/\/doi.org\/10.1093\/cid\/cit306.","journal-title":"Clin Infect Dis"},{"key":"623_CR38","volume-title":"Hepatitis C among drug users in Europe: epidemiology, treatment and prevention","author":"EMCDDA","year":"2016","unstructured":"EMCDDA. Hepatitis C among drug users in Europe: epidemiology, treatment and prevention. Lisbon: Publications Office; 2016. https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/2953\/TDXD16002ENN_final_web.pdf"},{"key":"623_CR39","doi-asserted-by":"publisher","first-page":"e1208","DOI":"10.1016\/S2214-109X(17)30373-X","volume":"5","author":"S Larney","year":"2017","unstructured":"Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5:e1208\u201320. https:\/\/doi.org\/10.1016\/S2214-109X(17)30373-X.","journal-title":"Lancet Glob Health"},{"key":"623_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12954-018-0230-1","volume":"15","author":"R Bielen","year":"2018","unstructured":"Bielen R, Stumo SR, Halford R, Werling K, Reic T, St\u00f6ver H, et al. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries. Harm Reduct J. 2018;15:25. https:\/\/doi.org\/10.1186\/s12954-018-0230-1.","journal-title":"Harm Reduct J"},{"key":"623_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12954-017-0141-6","volume":"14","author":"L Wiessing","year":"2017","unstructured":"Wiessing L, Ferri M, B\u011bl\u00e1\u010dkov\u00e1 V, Carrieri P, Friedman SR, Folch C, et al. Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. Harm Reduct J. 2017;14:19. https:\/\/doi.org\/10.1186\/s12954-017-0141-6.","journal-title":"Harm Reduct J"}],"container-title":["Archives of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-021-00623-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13690-021-00623-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-021-00623-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T04:04:21Z","timestamp":1623125061000},"score":1,"resource":{"primary":{"URL":"https:\/\/archpublichealth.biomedcentral.com\/articles\/10.1186\/s13690-021-00623-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["623"],"URL":"https:\/\/doi.org\/10.1186\/s13690-021-00623-2","relation":{},"ISSN":["2049-3258"],"issn-type":[{"value":"2049-3258","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]},"assertion":[{"value":"27 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the research was granted by The Mater Misericordiae University Hospital Research Ethics Committee (Ref:1\/378\/1839) and the Irish Prison Service (IPS) Ethics Review Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}